Eosinophils and Lung Cancer: From Bench to Bedside.

biomarkers; eosinophils; immunotherapy; non-small cell lung cancer; predictive value; prognostic value; Biomarkers; Immune Checkpoint Inhibitors; Eosinophils/pathology; Humans; Immunotherapy; Carcinoma, Non-Small-Cell Lung/pathology; Lung Neoplasms/pathology; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistry; General Medicine

Abstract :

[en] Eosinophils are rare, multifunctional granulocytes. Their growth, survival, and tissue migration mainly depend on interleukin (IL)-5 in physiological conditions and on IL-5 and IL-33 in inflammatory conditions. Preclinical evidence supports an immunological role for eosinophils as innate immune cells and as agents of the adaptive immune response. In addition to these data, several reports show a link between the outcomes of patients treated with immune checkpoint inhibitors (ICI) for advanced cancers and blood eosinophilia. In this review, we present, in the context of non-small cell lung cancer (NSCLC), the biological properties of eosinophils and their roles in homeostatic and pathological conditions, with a focus on their pro- and anti-tumorigenic effects. We examine the possible explanations for blood eosinophilia during NSCLC treatment with ICI. In particular, we discuss the value of eosinophils as a potential prognostic and predictive biomarker, highlighting the need for stronger clinical data. Finally, we conclude with perspectives on clinical and translational research topics on this subject.

Disciplines :

Oncology

Author, co-author :

SIBILLE, Anne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

CORHAY, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Ninane, Vincent; Department of Pulmonary Medicine, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium

JERUSALEM, Guy ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

DUYSINX, Bernard ^✱; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Eosinophils and Lung Cancer: From Bench to Bedside.

Publication date :

03 May 2022

Journal title :

International Journal of Molecular Sciences

ISSN :

1661-6596

eISSN :

1422-0067

Publisher :

MDPI, Switzerland

Volume :

Issue :

Pages :

5066

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.mdpi.com/1422-0067/23/9/5066/pdf

Available on ORBi :

since 16 July 2022

Statistics

Number of views

145 (4 by ULiège)

Number of downloads

114 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

See more details

publications

supporting

mentioning

contrasting

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Bibliography

Kay, A.B. The early history of the eosinophil. Clin. Exp. Allergy 2015, 45, 575–582. [CrossRef] [PubMed]
GINA Guidelines. Global Initiative for Asthma. Available online: https://ginasthma.org/gina-reports/(accessed on 16 December 2021).
GOLD Guidelines. Global Initiative for Chronic Obstructive Lung Disease. Available online: https://goldcopd.org/2021-gold-reports/(accessed on 16 December 2021).
Delyon, J.; Mateus, C.; Lefeuvre, D.; Lanoy, E.; Zitvogel, L.; Chaput, N.; Roy, S.; Eggermont, A.M.M.; Routier, E.; Robert, C. Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival. Ann. Oncol. 2013, 24, 1697–1703. [CrossRef] [PubMed]
Tanizaki, J.; Haratani, K.; Hayashi, H.; Chiba, Y.; Nakamura, Y.; Yonesaka, K.; Kudo, K.; Kaneda, H.; Hasegawa, Y.; Tanaka, K.; et al. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J. Thorac. Oncol. 2018, 13, 97–105. Available online: https://www.ncbi.nlm.nih.gov/pubmed/29170120 (accessed on 28 April 2022). [CrossRef]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
Mori, Y.; Iwasaki, H.; Kohno, K.; Yoshimoto, G.; Kikushige, Y.; Okeda, A.; Uike, N.; Niiro, H.; Takenaka, K.; Nagafuji, K.; et al. Identification of the human eosinophil lineage-committed progenitor: Revision of phenotypic definition of the human common myeloid progenitor. J. Exp. Med. 2009, 206, 183–193. [CrossRef] [PubMed]
Iwasaki, H.; Mizuno, S.I.; Mayfield, R.; Shigematsu, H.; Arinobu, Y.; Seed, B.; Gurish, M.F.; Takatsu, K.; Akashi, K. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J. Exp. Med. 2005, 201, 1891–1897. [CrossRef] [PubMed]
Drissen, R.; Buza-Vidas, N.; Woll, P.; Thongjuea, S.; Gambardella, A.; Giustacchini, A.; Mancini, E.; Zriwil, A.; Lutteropp, M.; Grover, A.; et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. Nat. Immunol. 2016, 17, 666–676. [CrossRef]
Mack, E.A.; Pear, W.S. Transcription factor and cytokine regulation of eosinophil lineage commitment. Curr. Opin. Hematol. 2020, 27, 27–33. [CrossRef]
Mishra, A.; Hogan, S.P.; Brandt, E.B.; Wagner, N.; Crossman, M.W.; Foster, P.S.; Rothenberg, M.E. Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J. Biol. Chem. 2002, 277, 4406–4412. [CrossRef]
Foster, P.S.; Hogan, S.P.; Ramsay, A.J.; Matthaei, K.I.; Young, I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 1996, 183, 195–201. [CrossRef]
Walsh, G.M. Anti-IL-5 monoclonal antibodies for the treatment of asthma: An update. Expert Opin. Biol. Ther. 2020, 20, 1237–1244. [CrossRef] [PubMed]
Fulkerson, P.C.; Schollaert, K.L.; Bouffi, C.; Rothenberg, M.E. IL-5 Triggers a Cooperative Cytokine Network That Promotes Eosinophil Precursor Maturation. J. Immunol. 2014, 193, 4043–4052. [CrossRef] [PubMed]
Steinbach, K.; Schick, P.; Trepel, F.; Raffler, H.; Döhrmann, J.; Heilgeist, G.; Heltzel, W.; Li, K.; Past, W.; van der Woerd-de Lange, J.; et al. Estimation of Kinetic Parameters of Neutrophilic, Eosinophilic, and Basophilic Granulocytes in Human Blood. Blut 1979, 39, 27–38. [CrossRef] [PubMed]
Mishra, A.; Hogan, S.P.; Lee, J.J.; Foster, P.S.; Rothenberg, M.E. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J. Clin. Investig. 1999, 103, 1719–1727. [CrossRef] [PubMed]
Gouon-Evans, V.; Pollard, J.W. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology 2001, 142, 4515–4521. [CrossRef]
Gouon-Evans, V.; Lin, E.Y.; Pollard, J.W. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res. 2002, 4, 155–164. [CrossRef]
Moser, R.; Fehr, J.; Bruinzeel, P.L.B. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J. Imunol. 1992, 149, 1432–1438.
Horie, S.; Okubo, Y.; Hossain, M.; Sato, E.; Nomura, H.; Koyama, S.; Suzuki, J.I.; Isobe, M.; Sekiguchi, M. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern. Med. 1997, 36, 179–185. [CrossRef]
Sher, A.; Coffman, R.L.; Hieny, S.; Cheever, A.W. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J. Immunol. 1990, 145, 3911–3916. Available online: http://www.ncbi.nlm.nih.gov/pubmed/2123226 (accessed on 28 April 2022).
Milovanovic, M.; Volarevic, V.; Radosavljevic, G.; Jovanovic, I.; Pejnovic, N.; Arsenijevic, N.; Lukic, M.L. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 2012, 52, 89–99. [CrossRef]
Bochner, B.S.; Schleimer, R.P. The role of adhesion molecules in human eosinophil and basophil recruitment. J. Allergy Clin. Immunol. 1994, 94, 427–438. [CrossRef]
Zimmermann, N.; Hershey, G.K.; Foster, P.S.; Rothenberg, M.E. Chemokines in asthma: Cooperative interaction between chemokines and IL-13. J. Allergy Clin. Immunol. 2003, 111, 227–243. [PubMed]
Kita, H.; Adolphson, C.R.; Gleich, G.J. Biology of Eosinophils. In Allergy: Principles and Practice, 4th ed.; Mosby: St Louis, MO, USA, 1998.
Sur, S.; Adolphson, C.R.; Gleich, G.J. Eosinophils: Biochemical and cellular aspects. In Allergy: Principles and Practice, 4th ed.; Mosby: St Louis, MO, USA, 1998.
Gleich, G.J.; Adolphson, C.R.; Leiferman, K.M. The biology of the eosinophilic leukocyte. Annu. Rev. Med. 1993, 44, 85–101. [CrossRef] [PubMed]
Hogan, S.P.; Rosenberg, H.F.; Moqbel, R.; Phipps, S.; Foster, P.S.; Lacy, P.; Kay, A.B.; Rothenberg, M.E. Eosinophils: Biological properties and role in health and disease. Clin. Exp. Allergy 2008, 38, 709–750. [CrossRef] [PubMed]
Kvarnhammar, A.M.; Cardell, L.O. Pattern-recognition receptors in human eosinophils. Immunology 2012, 136, 11–20. [CrossRef]
Lucarini, V.; Ziccheddu, G.; Macchia, I.; La Sorsa, V.; Peschiaroli, F.; Buccione, C.; Sistigu, A.; Sanchez, M.; Andreone, S.; D’Urso, M.T.; et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology 2017, 6, e1317420. [CrossRef]
Andreone, S.; Spadaro, F.; Buccione, C.; Mancini, J.; Tinari, A.; Sestili, P.; Gambardella, A.R.; Lucarini, V.; Ziccheddu, G.; Parolini, I.; et al. IL-33 promotes CD11b/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers 2019, 11, 1664. [CrossRef]
Lee, J.J.; Rosenberg, H.F. Eosinophils in Health and Disease; Academic Press: Cambridge, MA, USA, 2013; pp. 111–119.
Croxford, A.L.; Buch, T. Cytokine reporter mice in immunological research: Perspectives and lessons learned. Immunology 2011, 132, 1–8. [CrossRef]
Zhang, J.; Lathbury, L.J.; Salamonsen, L.A. Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium. Biol. Reprod. 2000, 62, 404–411. [CrossRef]
Timmons, B.C.; Fairhurst, A.-M.; Mahendroo, M.S. Temporal Changes in Myeloid Cells in the Cervix during Pregnancy and Parturition. J. Immunol. 2009, 182, 2700–2707. [CrossRef]
Chu, V.T.; Beller, A.; Rausch, S.; Strandmark, J.; Zänker, M.; Arbach, O.; Kruglov, A.; Berek, C. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity 2014, 40, 582–593. [CrossRef] [PubMed]
Goh, Y.P.S.; Henderson, N.C.; Heredia, J.E.; Eagle, A.R.; Odegaard, J.I.; Lehwald, N.; Nguyen, K.D.; Sheppard, D.; Mukundan, L.; Locksley, R.M.; et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc. Natl. Acad. Sci. USA 2013, 110, 9914–9919. [CrossRef] [PubMed]
Heredia, J.E.; Mukundan, L.; Chen, F.M.; Mueller, A.A.; Deo, R.C.; Locksley, R.M.; Rando, T.A.; Chawla, A. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 2013, 153, 376–388. [CrossRef] [PubMed]
Wu, D.; Molofsky, A.B.; Liang, H.E.; Ricardo-Gonzalez, R.R.; Jouihan, H.A.; Bando, J.K.; Chawla, A.; Locksley, R.M. Eosinophils Sustain Adipose Alternatively Activated macrophages Associated with Glucose Homeostasis. Science 2011, 332, 243–247. [CrossRef]
Qiu, Y.; Nguyen, K.D.; Odegaard, J.I.; Cui, X.; Tian, X.; Locksley, R.M.; Palmiter, R.D.; Chawla, A. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 2014, 157, 1292–1308. [CrossRef]
Wang, H.-B.; Weller, P.F. Pivotal Advance: Eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J. Leukoc. Biol. 2008, 83, 817–821. [CrossRef]
Jordan, M.B.; Mills, D.M.; Kappler, J.; Marrack, P.; Cambier, J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004, 304, 1808–1810. [CrossRef]
Chu, V.T.; Fröhlich, A.; Steinhauser, G.; Scheel, T.; Roch, T.; Fillatreau, S.; Lee, J.J.; Löhning, M.; Berek, C. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 2011, 12, 151–159. [CrossRef]
Berek, C. Eosinophils: Important players in humoral immunity. Clin. Exp. Immunol. 2016, 183, 57–64. [CrossRef]
Mantis, N.J.; Rol, N.; Corthésy, B. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 2011, 4, 603–611. [CrossRef]
Odemuyiwa, S.O.; Ghahary, A.; Li, Y.; Puttagunta, L.; Lee, J.E.; Musat-Marcu, S.; Ghahary, A.; Moqbel, R. Cutting Edge: Human Eosinophils Regulate T Cell Subset Selection through Indoleamine 2,3-Dioxygenase. J. Immunol. 2004, 173, 5909–5913. [CrossRef] [PubMed]
Varricchi, G.; Galdiero, M.R.; Loffredo, S.; Lucarini, V.; Marone, G.; Mattei, F.; Marone, G.; Schiavoni, G. Eosinophils: The unsung heroes in cancer? Oncoimmunology 2018, 7, e1393134. [CrossRef] [PubMed]
Huang, M.; Wang, J.; Lee, P.; Sharma, S.; Mao, J.T.; Meissner, H.; Dubinett, S.M.; Dubinett, S.M.; Uyemura, K.; Modlin, R.; et al. Human Non-Small Cell Lung Cancer Cells Express a Type 2 Cytokine Pattern. Cancer Res. 1995, 55, 3847–3853. [PubMed]
Curran, C.S.; Evans, M.D.; Bertics, P.J. GM-CSF Production by Glioblastoma Cells Has a Functional Role in Eosinophil Survival, Activation, and Growth Factor Production for Enhanced Tumor Cell Proliferation. J. Immunol. 2011, 187, 1254–1263. [CrossRef] [PubMed]
Simson, L.; Ellyard, J.I.; Dent, L.A.; Matthaei, K.I.; Rothenberg, M.E.; Foster, P.S.; Smyth, M.J.; Parish, C.R. Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance. J. Immunol. 2007, 178, 4222–4229. [CrossRef] [PubMed]
Hollande, C.; Boussier, J.; Ziai, J.; Nozawa, T.; Bondet, V.; Phung, W.; Lu, B.; Duffy, D.; Paradis, V.; Mallet, V.; et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol. 2019, 20, 257–264. [CrossRef] [PubMed]
Cormier, S.A. Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 2006, 79, 1131–1139. [CrossRef]
Lotfi, R.; Herzog, G.I.; DeMarco, R.A.; Beer-Stolz, D.; Lee, J.J.; Rubartelli, A.; Schrezenmeier, H.; Lotze, M.T. Eosinophils Oxidize Damage-Associated Molecular Pattern Molecules Derived from Stressed Cells. J. Immunol. 2009, 183, 5023–5031. [CrossRef]
Reichman, H.; Itan, M.; Rozenberg, P.; Yarmolovski, T.; Brazowski, E.; Varol, C.; Gluck, N.; Shapira, S.; Arber, N.; Qimron, U.; et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol. Res. 2019, 7, 388–400. [CrossRef]
Tepper, R.I.; Coffman, R.L.; Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992, 257, 548–551. [CrossRef]
Legrand, F.; Driss, V.; Delbeke, M.; Loiseau, S.; Hermann, E.; Dombrowicz, D.; Capron, M. Human Eosinophils Exert TNF-α and Granzyme A-Mediated Tumoricidal Activity toward Colon Carcinoma Cells. J. Immunol. 2010, 185, 7443–7451. [CrossRef] [PubMed]
Carretero, R.; Sektioglu, I.M.; Garbi, N.; Salgado, O.C.; Beckhove, P.; Hämmerling, G.J. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 2015, 16, 609–617. Available online: https://www.ncbi.nlm.nih.gov/pubmed/25915731 (accessed on 28 April 2022). [CrossRef] [PubMed]
O’Flaherty, S.M.; Sutummaporn, K.; Häggtoft, W.L.; Worrall, A.P.; Rizzo, M.; Braniste, V.; Höglund, P.; Kadri, N.; Chambers, B.J. TLR-Stimulated Eosinophils Mediate Recruitment and Activation of NK Cells In Vivo. Scand. J. Immunol. 2017, 85, 417–424. [CrossRef] [PubMed]
Lotfi, R.; Lotze, M.T. Eosinophils induce DC maturation, regulating immunity. J. Leukoc. Biol. 2008, 83, 456–460. [CrossRef]
Wong, D.T.W.; Bowen, S.M.; Elovic, A.; Gallagher, G.T.; Weller, P.F. Eosinophil ablation and tumor development. Oral Oncol. 1999, 35, 496–501. [CrossRef]
da Silva, J.M.; dos Santos, T.P.M.; Sobral, L.M.; Queiroz-Junior, C.M.; Rachid, M.A.; Proudfoot, A.E.I.; Garlet, G.P.; Batista, A.C.; Teixeira, M.M.; Leopoldino, A.M.; et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis. Oncotarget 2017, 8, 51024–51036. [CrossRef]
Xie, F.; Liu, L.B.; Shang, W.Q.; Chang, K.K.; Meng, Y.H.; Mei, J.; Yu, J.J.; Li, D.J.; Li, M.Q. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer Lett. 2015, 364, 106–117. [CrossRef]
Zaynagetdinov, R.; Sherrill, T.P.; Gleaves, L.A.; McLoed, A.G.; Saxon, J.A.; Habermann, A.C.; Connelly, L.; Dulek, D.; Peebles, R.S.; Fingleton, B.; et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015, 75, 1624–1634. Available online: https://www.ncbi.nlm.nih.gov/pubmed/25691457 (accessed on 28 April 2022). [CrossRef]
Astigiano, S.; Morandi, B.; Costa, R.; Mastracci, L.; D’Agostino, A.; Ratto, G.B.; Melioli, G.; Frumento, G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005, 7, 390–396. Available online: https://www.ncbi.nlm.nih.gov/pubmed/15967116 (accessed on 28 April 2022). [CrossRef]
Kratochvill, F.; Neale, G.; Haverkamp, J.M.; de Velde, L.A.; Smith, A.M.; Kawauchi, D.; McEvoy, J.; Roussel, M.F.; Dyer, M.A.; Qualls, J.E.; et al. TNF Counterbalances the Emergence of M2 Tumor Macrophages. Cell Rep. 2015, 12, 1902–1914. Available online: https://www.ncbi.nlm.nih.gov/pubmed/26365184 (accessed on 28 April 2022). [CrossRef]
Grisaru-Tal, S.; Itan, M.; Klion, A.D.; Munitz, A. A new dawn for eosinophils in the tumour microenvironment. Nat. Rev. Cancer 2020, 20, 594–607. [CrossRef] [PubMed]
Shalapour, S.; Karin, M. Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. Immunity 2019, 51, 15–26. [CrossRef] [PubMed]
Greten, F.R.; Grivennikov, S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 2019, 51, 27–41. [CrossRef] [PubMed]
Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 2010, 11, 889–896. [CrossRef]
Mattei, F.; Andreone, S.; Marone, G.; Gambardella, A.R.; Loffredo, S.; Varricchi, G.; Schiavoni, G. Eosinophils in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020, 1273, 1–28.
Abdala Valencia, H.; Loffredo, L.F.; Misharin, A.V.; Berdnikovs, S. Phenotypic plasticity and targeting of Siglec-FhighCD11clow eosinophils to the airway in a murine model of asthma. Allergy Eur. J. Allergy Clin. Immunol. 2016, 71, 267–271. [CrossRef]
Percopo, C.M.; Brenner, T.A.; Ma, M.; Kraemer, L.S.; Hakeem, R.M.A.; Lee, J.J.; Rosenberg, H.F. SiglecF + Gr1 hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice. J. Leukoc. Biol. 2017, 101, 321–328. [CrossRef]
Mesnil, C.; Raulier, S.; Paulissen, G.; Xiao, X.; Birrell, M.A.; Pirottin, D.; Janss, T.; Starkl, P.; Ramery, E.; Henket, M.; et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J. Clin. Investig. 2016, 126, 3279–3295. [CrossRef]
Rosenberg, S.; Lotze, M.T.; Muul, L.; Leitman, S.; Chang, A.; Ettinghausen, S.; Matory, Y.; Skibber, J.; Shiloni, E.; JT, V. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313, 1485–1492. [CrossRef]
van Haelst Pisani, C.; Kovach, J.; Kita, H.; Leiferman, K.; Gleich, G.; Silver, J.; Dennin, R.; Abrams, J. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991, 78, 1538–1544. [CrossRef]
Gebhardt, C.; Sevko, A.; Jiang, H.; Lichtenberger, R.; Reith, M.; Tarnanidis, K.; Holland-Letz, T.; Umansky, L.; Beckhove, P.; Sucker, A.; et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin. Cancer Res. 2015, 21, 5453–5459. Available online: https://www.ncbi.nlm.nih.gov/pubmed/26289067 (accessed on 28 April 2022). [CrossRef] [PubMed]
Martens, A.; Wistuba-Hamprecht, K.; Foppen, M.G.; Yuan, J.; Postow, M.A.; Wong, P.; Romano, E.; Khammari, A.; Dreno, B.; Capone, M.; et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 2016, 22, 2908–2918. [CrossRef] [PubMed]
Weide, B.; Martens, A.; Hassel, J.C.; Berking, C.; Postow, M.A.; Bisschop, K.; Simeone, E.; Mangana, J.; Schilling, B.; Di Giacomo, A.M.; et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin. Cancer Res. 2016, 22, 5487–5496. Available online: https://www.ncbi.nlm.nih.gov/pubmed/27185375 (accessed on 28 April 2022). [CrossRef] [PubMed]
Moreira, A.; Leisgang, W.; Schuler, G.; Heinzerling, L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy 2017, 9, 115–121. Available online: https://www.ncbi.nlm.nih. gov/pubmed/28128709 (accessed on 28 April 2022). [CrossRef]
Bernard-Tessier, A.; Jeanville, P.; Champiat, S.; Lazarovici, J.; Voisin, A.L.; Mateus, C.; Lambotte, O.; Annereau, M.; Michot, J.M. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur. J. Cancer 2017, 81, 135–137. Available online: https://www.ncbi.nlm.nih.gov/pubmed/28624693 (accessed on 28 April 2022). [CrossRef]
Chu, X.; Zhao, J.; Zhou, J.; Zhou, F.; Jiang, T.; Jiang, S.; Sun, X.; You, X.; Fengying, F.; Ren, S.; et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer 2020, 150, 76–82. [CrossRef]
Sibille, A.; Henket, M.; Corhay, J.L.; Alfieri, R.; Louis, R.; Duysinx, B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021, 199, 549–557. [CrossRef]
Okauchi, S.; Shiozawa, T.; Miyazaki, K.; Nishino, K.; Sasatani, Y.; Ohara, G.; Kagohashi, K.; Sato, S.; Kodama, T.; Satoh, H.; et al. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Polish Arch. Intern. Med. 2021, 131, 152–160. [CrossRef]
Voorwerk, L.; Garner, H.; Blomberg, O.S.; Spagnuolo, L.; Chalabi, M.; van Dyk, E.; Isaeva, O.I.; Bakker, N.; Klaver, C.; Duijst, M.; et al. LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types. Ann. Oncol. 2020, 31, S1142. [CrossRef]
Postow, M.A.; Hellmann, M.D. Adverse Events Associated with Immune Checkpoint Blockade. N. Engl. J. Med. 2018, 378, 1165. Available online: https://www.ncbi.nlm.nih.gov/pubmed/29562154 (accessed on 28 April 2022). [CrossRef]
Scanvion, Q.; Béné, J.; Gautier, S.; Grandvuillemin, A.; Le Beller, C.; Chenaf, C.; Etienne, N.; Brousseau, S.; Cortot, A.B.; Mortier, L.; et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Oncoimmunology 2020, 9, 1722022. [CrossRef] [PubMed]
Yamaguchi, Y.; Suda, T.; Shiozaki, H.; Miura, Y.; Hitoshi, Y.; Takatsu, K.; Kasahara, T. Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2. J. Immunol. 2021, 45, 873–877.
Van Gool, F.; Molofsky, A.B.; Morar, M.M.; Rosenzwajg, M.; Liang, H.E.; Klatzmann, D.; Locksley, R.M.; Bluestone, J.A. Interleukin-5—Producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 2014, 124, 3572–3576. [CrossRef]
Werner, J.P. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 2003, 139, 683–693.
Ye, L.; Wang, H.; Li, H.; Liu, H.; Lv, T.; Song, Y.; Zhang, F. Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma. J. Cancer 2019, 10, 1032–1038. [CrossRef] [PubMed]
Tataroǧlu, C.; Kargi, A.; Özkal, S.; Eşrefoǧlu, N.; Akkoçlu, A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 2004, 43, 47–54. [CrossRef] [PubMed]
Weller, P.F.; Spencer, L.A. Functions of tissue-resident eosinophils. Nat. Rev. Immunol. 2017, 17, 746–760. [CrossRef]
Van Hulst, G.; Batugedara, H.M.; Jorssen, J.; Louis, R.; Bureau, F.; Desmet, C.J. Eosinophil diversity in asthma. Biochem. Pharmacol. 2020, 179, 113963. [CrossRef]
Dolitzky, A.; Shapira, G.; Grisaru-Tal, S.; Hazut, I.; Avlas, S.; Gordon, Y.; Itan, M.; Shomron, N.; Munitz, A. Transcriptional Profiling of Mouse Eosinophils Identifies Distinct Gene Signatures Following Cellular Activation. Front. Immunol. 2021, 12, 5288. [CrossRef]
Van Rossem, I.; Hanon, S.; Verbanck, S.; Vanderhelst, E. Blood Eosinophil Counts in COPD: Adding Within-day Variability to the Equation. Am. J. Respir. Crit. Care Med. 2021, 205, 727–729. [CrossRef]
Abrahamsen, J.F.; Smaaland, R.; Sandberg, S.; Aakvaag, A.; Lote, K. Circadian variation in serum cortisol and circulating neutrophils are markers for circadian variation of bone marrow proliferation in cancer patients. Eur. J. Haematol. 1993, 50, 206–212. [CrossRef] [PubMed]

Similar publications

Sorry the service is unavailable at the moment. Please try again later.

Name	Provider / Domaine	Expiration	Description
JSESSIONID	Oracle Corporation www.uliege.be	Session	General purpose platform session cookie, used by sites written in JSP. Usually used to maintain an anonymous user session by the server.
CookieScriptConsent	CookieScript .uliege.be	1 year	This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.

Name	Provider / Domaine	Expiration	Description
_pk_id	InnoCraft Ltd .uliege.be	1 year	Used to store a few details about the user such as the unique visitor ID
_pk_ses	InnoCraft Ltd .uliege.be	30 minutes	Short lived cookies used to temporarily store data for the visit
_pk_ref	InnoCraft Ltd .uliege.be	6 months	Used to store the attribution information, the referrer initially used to visit the website